he practice of interventional cardiology is a daily source of instant gratification: identify a critical coronary lesion, implant a stent, and obtain a pristine result. The use of an Impella device in cardiogenic shock is on the top of this satisfaction list: a patient with an acute myocardial infarction (AMI) complicated by cardiogenic shock (AMI-CS), confused and crashing with low systolic blood pressure, is rushed into the catheritization laboratory, an Impella CP is implanted in 10 minutes flat, the start button is pushed, the blood pressure rises, the patient regains consciousness, and percutaneous coronary intervention (PCI) is performed swiftly. The patient leaves the laboratory with an interventional cardiologist feeling on the top of the world that he has chosen the best therapeutic option. But what is the evidence supporting such practice? To date, there is no large randomized study comparing the use of Impella CP or other contemporary cardiac support devices and medical treatment in ST-segment-elevation myocardial infarction-related cardiogenic shock.
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WHAT DOES THIS STUDY SHOW?
In this issue of Circulation, Schrage et al 2 used a multinational database of AMI-CS cases treated with an Impella device to compare in a matched fashion the outcome to patients from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock II) trial, a randomized trial that demonstrated similar outcomes between the use of intra-aortic balloon pump (IABP) and medical treatment in AMI-CS. 3 With the use of IAPB-SHOCK II inclusion and exclusion criteria, 372 patients from the registry were included in the analysis and matched to 600 patients from the IABP-SHOCK II trial. Two hundred thirty-seven patients treated with Impella were matched to 237 patients from the IABP SHOCK II trial. There was no significant difference in 30-day allcause mortality (48.5% versus 46.4%; P=0.64). Severe or life-threatening bleeding (8.5% versus 3.0%; P<0.01) and peripheral vascular complications (9.8% versus 20 3.8%; P=0.01) occurred significantly more often in the Impella group. Several subgroup analyses were performed. Limiting the analysis to IABP-treated patients as a control group did not change the results. The Impella device was implanted before the procedure in 38.1% of cases. There was no difference in 30-day mortality between pre-and post-PCI implantation of the Impella device.
Randomized trials are on the top of the hierarchy of evidence. Matched casecontrol studies, such as Schrage et al's, are hypothesis-generating at best. Further-more, the validity of the matching can be questioned because differences between groups remain on important variables such as the incidence of coronary triplevessel disease, glomerular filtration rate, and blood pressure levels. The small sample size probably provides enough power for the main outcome in the total group. However, conclusions on the analyses in the subgroups are more difficult. In particular, the nonsignificant difference of 30-day mortality between pre-and post-PCI Impella implantation would have required a bigger sample size to show a significant difference between groups. Another limitation is the choice of the device: 74 of 237 patients in the Impella group were treated with the Impella 2.5, which delivers 2.5 L/min of support, whereas most patients with AMI-CS are currently implanted with an Impella CP, which provides a higher level of support (up to 3.7 L/min). Finally, the influence of a learning curve cannot be excluded, because a minimal number of Impella implantations per operator and per center were not required.
WHAT ARE THE IMPLICATIONS OF THE FINDINGS?
Despite these limitations, the authors should be congratulated for addressing an important clinical topic. Data on the use of cardiac assist devices in AMI-CS are mostly limited to registries. Randomized trials are scarce and, with the exception of the IABP SHOCK II trial, underpowered (Table) . Why have we not been able to produce large randomized trials? The rate of AMI-CS has declined in the past decades and is currently between 4% and 8%. 8 Furthermore, clinical signs of shock in AMI-CS appear in ≈50% to 75% of cases several hours after hospital admission, making randomization before primary PCI difficult. 9 Finally, many interventional cardiologists believe that equipoise has been reached on the use of cardiac-assist devices in AMI-CS with registry data and that it is unethical to randomly assign patients in trials. This is especially true in the United States, where Impella devices are approved and reimbursed based on registry data. The ongoing Danish Cardiogenic Shock (DanShock, NCT 01633502) trial started in 2012 and is comparing the use of Impella CP with conventional therapy in cardiogenic shock. The investigators have planned to enroll 360 patients over a period of 10 years, and, even at that pace, recruitment is difficult and behind schedule.
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WHAT ARE THE REMAINING GAPS?
Are we doomed to base our practice with cardiac assist devices in AMI-CS on data from registries? Thiele et al 3, 11 have demonstrated that swift and effective recruitment in randomized trials on AMI-CS is feasible based on a network of dedicated tertiary centers. The Impella CP offers a unique window of opportunity. Because of the absence of randomized trials, its use in AMI-CS is not approved or reimbursed in countries such as France and the United Kingdom. Investigators would be eager to enroll patients in a trial comparing standard therapy with the use of Impella CP. Because clinical signs of AMI-CS appear after admission, inclusion criteria could be focused on patients with preshock based on the presence of predictive factors for the occurrence of AMI-CS using validated scores. 12, 13 Encouraging data from registries coupled with a catheterization laboratory gut feeling led to the widespread adoption of interventional cardiology techniques or devices that were not sustained by randomized trials. The IABP was used for decades before the IABP SHOCK trial demonstrated no difference in 30-day mortality between IABP and PCI and PCI alone. Multiple stents were implanted in coronary bifurcations based on benchmark tests, supported by excitement generated by live cases and technical challenges before randomized studies showed that a single-stent strategy is the best option in most cases. Let us learn from history and not repeat the same mistakes with cardiac assist devices in AMI-CS. 
